Bronchial asthma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients who meet all of the following inclusion criteria will be enrolled in the study: 1) Patients who provide consent based on the informed consent document made available on the website 2) Men or women aged 20 years or older on the date of consent 3) Patients who have been diagnosed as having bronchial asthma* by a physician at least one year prior to the date of consent 4) Patients who have been prescribed an ICS or ICS/LABA continuously on the date of consent 5) Patients who have taken at least 80% of their prescribed medication of ICS or ICS/LABA during the month immediately prior to the date of consent * This study includes patients who reported their disease name as cough variant asthma because they may have not fully understood their diagnosis
Exclusion criteria
Exclusion criteria: Patients who meet the following criterion will be excluded from enrollment in the study: Patients who are unlikely to be able to follow the instructions for the study based on their completion status of questionnaires
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Types (psychological and activity limitations) and degrees of subjective burden based on the questions created for this study | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Demographic characteristics (e.g., age, BMI and smoking history) 2)Current asthma control level assessed using ACT 3)Current QOL assessed using AHQ-33, JAPAN 4)Degree of satisfaction with current treatment and the frequency of symptoms based on the questions created for this study 5)Expectations regarding treatment with antiasthmatic drugs based on the questions created for this study 6)Reproducibility of the questions on subjective burden based on the questions created for this study, and the correlation between the ACT and AHQ-33, JAPAN | — |
Countries
Japan
Contacts
Mebix, Inc. Research promotion division